Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene
✍ Scribed by Markus Müschen; Daniel Re; Beate Betz; Cordula Moers; Jürgen Wolf; Dieter Niederacher; Volker Diehl; Matthias W. Beckmann
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 45 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Resistance to CD95 (Apo-1/Fas)-mediated apoptosis is a typical feature of breast cancer cells. Recent studies identified deleterious mutations of the CD95 gene not only in a variety of B cell lymphomas but also in a number of solid tumor entities. Therefore, we amplified and sequenced selected regions of the CD95 gene from 48 breast cancer cases and 10 cell lines but no mutation was found. In the presence of both polymorphic alleles, loss of heterozygosity was excluded in 27 informative cases. We conclude, that relevant somatic mutations of the CD95 gene occur, if at all, at a low frequency and are not the primary cause for resistance to CD95-mediated apoptosis in breast cancer.